Amylyx Pharmaceuticals (AMLX) Assets (2021 - 2026)

Amylyx Pharmaceuticals' Assets history runs 6 years deep, the most recent figure standing at $293.6 million for Q1 2026.

• On a quarterly basis, Assets rose 33.65% year-over-year to $293.6 million in Q1 2026; TTM through Mar 2026 was $293.6 million, a 33.65% increase from a year earlier, with the FY2025 full-year figure at $332.6 million, up 71.79% from the prior year.
• Assets slipped to $293.6 million in Q1 2026 per AMLX's latest filing, from $332.6 million in the prior quarter.
• Across five years, Assets topped out at $517.5 million in Q4 2023 and bottomed at $181.4 million in Q3 2022.
• The 5-year median for Assets is $332.2 million (2024), against an average of $324.4 million.
• Across the five-year window, Assets surged 270.64% in 2022 and plunged 62.58% in 2024, its largest moves.
• Year by year, Assets stood at $391.5 million in 2022, then jumped by 32.19% to $517.5 million in 2023, then plunged by 62.58% to $193.6 million in 2024, then soared by 71.79% to $332.6 million in 2025, then fell by 11.74% to $293.6 million in 2026.
• Per Business Quant, the three latest AMLX Assets figures stand at $293.6 million (Q1 2026), $332.6 million (Q4 2025), and $362.7 million (Q3 2025).